News | October 16, 2008

EPIC Carotid Stent Trial Reveals Low Stroke Rate

October 16, 2008 - Lumen Biomedical Inc. said that Principal Investigator Subbarao V. Myla, M.D., presented the results from the EPIC clinical trial — “Evaluating the Use of the FiberNet Embolic Protection System in Carotid Artery Stenting” — at TCT 2008.

From March 2007 to May 2008, the multicenter, single-arm EPIC clinical trial evaluated the FiberNet Embolic Protection System during carotid artery stenting of 237 high surgical risk patients with a critical carotid artery stenosis. The EPIC trial was an FDA IDE clinical study sponsored by Lumen Biomedical Inc.

“EPIC’s superior results stand alone; FiberNet EPS embodies all three successful requirements for safe carotid stenting, low profile, optimal filtration and ease of use,” Dr. Myla said. “The FiberNet System represents the best blend of science and clinical practice finding the right balance of optimal filtration with maintained safe perfusion.”

The FiberNet EPS captures particles released during the carotid artery stenting procedure with a filter made of a 3-dimensional matrix of fibers. The filter is designed to prevent microscopic debris from traveling to the brain. After the particles have been captured, the FiberNet filter is then retrieved into the retrieval catheter, Lumen Biomedical’s FDA-cleared Xtract Aspiration Catheter, and removed from the patient.

The mean age of the patients participating in the clinical trial was 74 years (21 percent were octagenarians), 64 percent male and 20 percent were symptomatic.

Overall, the combined major adverse event rate at 30 days for all death, stroke and myocardial infarction (MI) was 3 percent. There were 5 strokes (4 ischemic and 1 hemorrhagic) for a 30-day stroke rate of 2.1 percent. There were no unanticipated adverse device effects. The results demonstrate that FiberNet EPS' unique features may contribute to a lower stroke rate during carotid artery stenting in high surgical risk patients.

For more information: www.lumenbio.com

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init